drugset

drugset / Trial / NCT06636123

GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

NCT06636123 ↗

Phase 1 Recruiting 30 enrolled Virginia Commonwealth University

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.

Timeline

Start: 2025-02-18
Primary completion: 2027-04-30
Completion: 2031-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GZ17-6.02	Unknown	375 mg	Oral

Indications